Related Experiment Video
Updated: May 22, 2026

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
New perspectives on glutamate receptor antagonists as antidepressants
1Department of Biological Sciences, Konkuk University, Seoul, 143-701, Korea. cchung@konkuk.ac.kr
Abstract:
Classical antidepressants elevate the monoamine levels in the brain by preventing re-uptake of monoamines after release. Treatment of depression with monoamine re-uptake inhibitors is associated with low clinical efficacy and remission rate due to the delayed onset of therapeutic responses. Therefore, the development of alternative antidepressants is essential for successful treatment of this disease. Recently, glutamate receptor antagonists including ketamine and 2-methyl-6-(phenylethynyl)-pyridine (MPEP) have received wide attention as fast-acting therapeutic alternatives for treatment of depression.
More Related Videos
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antiepileptic Drugs: Glutamate Antagonists
Antidepressant Drugs: Overview
G-protein Coupled Receptors
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

